The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling ...

Amid a reckoning for the gene therapy field, Vertex Pharmaceuticals has joined a growing list of companies paring back their ...

To REMS, or not to REMS. That, apparently, was the question for Cytokinetics, which has seen any potential approval for its ...

Pliant Therapeutics will be cutting 45% of staffers as part of a “strategic restructuring of its workforce," the biotech ...

Tim Friede began willingly injecting himself with escalating doses of venom from 16 snake species. | Eighteen years ago, Tim ...

The United Kingdom aims to boost its life sciences profile as Aviva Capital Partners and Socius unveiled plans for a £1 ...

Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

Scholar Rock is shaking up its executive team as it prepares to enter the commercial arena with the expected launch of spinal ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...

An approval decision for Stealth BioTherapeutics’ investigational treatment for an ultra-rare genetic disease has been ...

Following the launch of two new cancer tests—plus a third planned for before the end of 2025—Exact Sciences is nudging up its ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...